ResultsIQ

ResultsIQ › Latest results › Granules India Limited

Granules India Limited Q3 FY26 earnings call summary

NSE: GRANULES · BSE: 532482

Earnings call of 23 Jan 2026, summarised by AI from the filing.

Ascelis Peptides expected to achieve EBITDA above neutrality in Q4 FY26 and positive in FY27.

Key takeaways

  1. Peptide guidance Ascelis Peptides expected to achieve EBITDA above neutrality in Q4 FY26 and positive in FY27.
  2. Preferential issue Shareholders approved preferential issue at EGM, strengthening balance sheet for growth.
  3. Complex generics Complex generics share rose to 49% of total contribution from 27% YoY.
  4. Gagillapur risk FDA re-inspection timeline uncertain; documentation to be submitted shortly.

Original filing on BSE

Granules India Limited Q1 FY27 results

As filed: Revenue ₹1,477 cr (+22% year on year), EBITDA ₹339 cr (+37% year on year), PAT ₹180 cr (+59% year on year), EBITDA margin 23.0% (+245 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,471 cr (+23% year on year), EBITDA ₹352 cr (+39% year on year), PAT ₹202 cr (+33% year on year), EBITDA margin 23.9% (+281 bps). Score 72 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin rose 281 bps year on year. Profit rose ₹49.6 cr on a year ago, more than the ₹22.0 cr it added the year before. Share price after the results: +9.7% in 30 days (Nifty 500: −0.5%).
  • Q3 FY26: Revenue ₹1,388 cr (+22% year on year), EBITDA ₹308 cr (+33% year on year), PAT ₹150 cr (+27% year on year), EBITDA margin 22.2% (+190 bps). Score 65 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin rose 190 bps year on year. Share price after the results: +9.5% in 28 days (Nifty 500: +3.0%).
  • Q2 FY26: Revenue ₹1,297 cr (+34% year on year), EBITDA ₹278 cr (+36% year on year), PAT ₹131 cr (+35% year on year), EBITDA margin 21.4% (+34 bps). Score 69 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin rose 34 bps year on year. Share price after the results: +5.9% in 29 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹1,210 cr (+3% year on year), EBITDA ₹248 cr (−4% year on year), PAT ₹113 cr (−6% year on year), EBITDA margin 20.5% (−145 bps). Score 42 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were below it. EBITDA margin fell 145 bps year on year. Share price after the results: +19.4% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹1,197 cr (+2% year on year), EBITDA ₹253 cr (−1% year on year), PAT ₹152 cr (−5% year on year), EBITDA margin 21.1% (−63 bps). Score 42 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were below it. EBITDA margin fell 63 bps year on year. Share price after the results: −6.0% in 30 days (Nifty 500: +3.5%).
  • Q3 FY25: Revenue ₹1,138 cr (−2% year on year), EBITDA ₹231 cr (−8% year on year), PAT ₹118 cr (−6% year on year), EBITDA margin 20.3% (−133 bps). Score 36 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 133 bps year on year.
  • Q2 FY25: Revenue ₹967 cr (−19% year on year), EBITDA ₹204 cr (−4% year on year), PAT ₹97.0 cr (−5% year on year), EBITDA margin 21.1% (+318 bps). Score 28 of 100, Below trend. EBITDA margin rose 318 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 18% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Granules India Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.